An interdisciplinary team led by Harvard’s Wyss Institute used AI-driven dynamic molecular modeling to develop bemcentinib, an FDA-approved oral drug repurposed to target coronaviruses effectively. Building on this, the team designed improved antivirals active against multiple respiratory coronaviruses, aiming to address vaccine hesitancy and variant resistance issues. Their computational-experimental platform integrates physics-based modeling with artificial intelligence and has published results demonstrating broad activity and potential for rapid deployment.